Navigation Links
Roche Venture Fund, Enterprise Ireland Commit EUR3.3 M to Opsona Series B Financing

DUBLIN, May 19 /PRNewswire/ --

- Completed Series B Total Stands at EUR21.3 m

Opsona Therapeutics, a biotechnology company focused on novel therapeutic and preventative approaches to autoimmune and inflammatory diseases, today announced that Roche Venture Fund and Enterprise Ireland have committed an additional EUR3.3 million to the Series B financing announced in February this year, bringing the total round to EUR21.3 million. The new investors join Novartis Venture Fund, Fountain Healthcare Partners, Inventages Venture Capital and Seroba-Kernel in completing the round, which will enable Opsona to further expand its clinical development pipeline.

Proceeds will support the advancement of Opsona's clinical trials targeting inflammatory diseases such as rheumatoid arthritis, lupus and solid organ transplant rejection. It will also be used to improve Opsona's capability to clinically evaluate novel compounds for in-licensing aimed at treating autoimmune and inflammatory diseases.

Commenting on the announcement, Mark Heffernan, Chief Executive Officer of Opsona Therapeutics, said: "We are delighted by the calibre of investors who have supported our Series B financing. The investment by Roche Venture Fund is a further endorsement of Opsona's approach to targeting the innate immune system, and the continued support of Enterprise Ireland demonstrates their commitment to investment in high-potential companies. This completed

Series B round of EUR21.3 million places Opsona in a strong financial position, which will enable us to continue to achieve our clinical and operational goals over the next three years."

"Roche is excited about investing in Opsona," said Carole Nuechterlein, Head of the Roche Venture Fund. "Opsona's scientific founder, Professor Luke O'Neill of Trinity College Dublin, is world renowned for his expertise in Toll-like receptors and innate immunity."

Commenting on today's announcement John O'Dea, Head of Lifesciences in the High Potential Start Up department in Enterprise Ireland said: "Opsona epitomises the type of innovative high potential company that EI is keen to support, and shows what can be achieved when the ambition and energy of a company are harnessed and supported. The company has a solid business strategy and strong links with industry and universities. Opsona has grown its product pipeline by investing intensively in collaborative R & D."

Notes to Editors:

About Opsona Therapeutics - Opsona is a drug development company, focused on novel therapeutic and preventative approaches to autoimmune and inflammatory diseases. The company was founded in 2004 by three of Trinity College Dublin's respected Immunologists. Opsona has a pipeline of therapeutics in advanced pre-clinical development which modulate the innate immune system, including biologics and small molecules. Opsona's lead product, a fully humanized monoclonal antibody (OPN-305) has demonstrated efficacy in a number of animal models and will start pivotal clinical trials in 2010. The company has also signed significant partnering and collaborative deals, with companies like Wyeth (USA). Headquartered in Dublin, Opsona also has laboratories in Lausanne, Switzerland.

About Roche Venture Fund - The Roche Venture Fund makes investments in early stage biotech and diagnostics companies to support innovative technologies and medicines. Based in Basel, Switzerland, the Roche Venture Fund manages a portfolio of over 30 companies in 10 countries.

About Enterprise Ireland - Enterprise Ireland is the government agency responsible for the development of Irish industry. Its core mission is to accelerate the development of world - class Irish companies to achieve strong positions in global markets resulting in increased national and regional prosperity.

For media queries, please contact:

Niamh Lyons - +353-1-6633602 or Jonathan Birt - +44-20-7269-7205

SOURCE Opsona Therapeutics Ltd
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Roche Announces Long-Term Commitment to Tackle Growing Epidemic of Diabetes
2. Codexis R&D Productivity Panels Also Used By Roche
3. Roche Madison Moves to New Facility
4. BioDuro and Roche Expand Strategic Collaboration to Provide Drug Discovery Services
5. Roche to Introduce New LightCycler(R) MRSA Advanced Test in the EU
6. Roche Completes Tender Offer for Genentech
7. Roche and Genentech Reach a Friendly Agreement to Combine the Two Organizations and Create a Leader in Healthcare Innovation
8. SD Canada Announces CE Mark for ThyroChek(R) Adult and NeoNatal Tests
9. Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors
10. Roche Intends to Commence Tender Offer to Acquire All Shares of Genentech for US$ 86.50 Per Share in Cash
11. Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
Post Your Comments:
(Date:11/24/2015)... Mass. (PRWEB) , ... November 24, 2015 , ... ... to maintain healthy metabolism. But unless it is bound to proteins, copper is ... of Health (NIH), researchers at Worcester Polytechnic Institute (WPI) will conduct a systematic ...
(Date:11/24/2015)... -- Clintrax Global, Inc., a worldwide provider of clinical research services headquartered ... the company has set a new quarterly earnings record in Q3 ... posted for Q3 of 2014 to Q3 of 2015.   ... , with the establishment of an Asia-Pacific ... United Kingdom and Mexico , with ...
(Date:11/24/2015)... ... , ... The Academy of Model Aeronautics (AMA), led by its Executive Council, ... Grand Prix, to represent the First–Person View (FPV) racing community. , FPV racing has ... type of racing and several new model aviation pilots have joined the community because ...
(Date:11/24/2015)... Israel , Nov. 24, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) ... on December 29, 2015 at 11:00 a.m. Israel ... Electra Tower, 98 Yigal Allon Street, 36 th Floor, ... of Eric Paneth and Izhak Tamir to the ... Rami Skaliter as external directors; , approval of an amendment to ...
Breaking Biology Technology:
(Date:11/2/2015)...  SRI International has been awarded a contract of ... to the National Cancer Institute (NCI) PREVENT Cancer Program ... modern testing and support facilities, and analytical instrumentation to ... studies to evaluate potential cancer prevention drugs. ... Drug Development Program is an NCI-supported pipeline to bring ...
(Date:10/29/2015)... 29, 2015  The J. Craig Venter Institute (JCVI) ... Synthesis and Biosecurity: Lessons Learned and Options for the ... and Human Services guidance for synthetic biology providers has ... --> --> Synthetic biology ... potential to pose unique biosecurity threats. It now is ...
(Date:10/29/2015)... ANN ARBOR, Mich. , Oct. 29, 2015 ... with Eurofins Genomics for U.S. distribution of its ... DNA-seq kit and Rubicon,s new ThruPLEX Plasma-seq ... DNA to enable the preparation of NGS libraries ... in plasma for diagnostic and prognostic applications in ...
Breaking Biology News(10 mins):